CN1094046A - 取代的黄嘌呤衍生物 - Google Patents

取代的黄嘌呤衍生物 Download PDF

Info

Publication number
CN1094046A
CN1094046A CN93107586A CN93107586A CN1094046A CN 1094046 A CN1094046 A CN 1094046A CN 93107586 A CN93107586 A CN 93107586A CN 93107586 A CN93107586 A CN 93107586A CN 1094046 A CN1094046 A CN 1094046A
Authority
CN
China
Prior art keywords
compound
formula
medicine
expression
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93107586A
Other languages
English (en)
Chinese (zh)
Inventor
A·E·芬韦克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1094046A publication Critical patent/CN1094046A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN93107586A 1992-05-21 1993-05-20 取代的黄嘌呤衍生物 Pending CN1094046A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929210839A GB9210839D0 (en) 1992-05-21 1992-05-21 Novel compounds
GB9210839.8 1992-05-21

Publications (1)

Publication Number Publication Date
CN1094046A true CN1094046A (zh) 1994-10-26

Family

ID=10715834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93107586A Pending CN1094046A (zh) 1992-05-21 1993-05-20 取代的黄嘌呤衍生物

Country Status (10)

Country Link
EP (1) EP0641344A1 (es)
JP (1) JPH07506591A (es)
CN (1) CN1094046A (es)
AU (1) AU4081493A (es)
CA (1) CA2136196A1 (es)
GB (1) GB9210839D0 (es)
MX (1) MX9302957A (es)
TW (1) TW277062B (es)
WO (1) WO1993023401A1 (es)
ZA (1) ZA933494B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
ES2222614T3 (es) 1997-11-12 2005-02-01 Mitsubishi Chemical Corporation Derivados de purina y medicina que los contiene como ingrediente activo.
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
DE60006663T2 (de) 1999-05-11 2004-10-07 Mitsubishi Chem Corp Dihydrat eines purinderivates, medikamente die dieses als aktiven wirkstoff enthalten und zwischenprodukte zu dessen herstellung
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2001016134A1 (en) * 1999-08-31 2001-03-08 Vanderbilt University Selective antagonists of a2b adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
US7495004B2 (en) 2002-06-17 2009-02-24 Glaxo Group Limited Purine derivatives as liver X receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
ATE363483T1 (de) 2003-07-31 2007-06-15 Schering Corp Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
CA2583185A1 (en) 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
KR101494125B1 (ko) 2006-02-03 2015-02-16 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2033922T3 (es) * 1986-08-28 1993-04-01 Sandoz Ag Procedimiento para preparar nuevos derivados de xantina.
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
CA2098846A1 (en) * 1990-12-21 1992-06-22 David G. Smith Xanthine derivatives

Also Published As

Publication number Publication date
EP0641344A1 (en) 1995-03-08
AU4081493A (en) 1993-12-13
TW277062B (es) 1996-06-01
ZA933494B (en) 1994-03-01
GB9210839D0 (en) 1992-07-08
JPH07506591A (ja) 1995-07-20
MX9302957A (es) 1994-05-31
CA2136196A1 (en) 1993-11-25
WO1993023401A1 (en) 1993-11-25

Similar Documents

Publication Publication Date Title
CN1094046A (zh) 取代的黄嘌呤衍生物
Krämer et al. Bruton tyrosine kinase inhibitors for multiple sclerosis
EP1778224B1 (en) Flt3 inhibitors for immune suppression
KR102241258B1 (ko) 암을 치료하기 위한 1-테트라히드로피라닐카르보닐-2,3-디히드로-1h-인돌 화합물
AU669702B2 (en) Enantiomeric hydroxylated xanthine compounds
TWI783978B (zh) Tyk2抑制劑、其用途及生產方法
JP3131225B2 (ja) Ｎ−（アロイル）グリシンヒドロキサム酸誘導体および関連化合物
US6767908B2 (en) Substituted imidazoles having cytokine inhibitory activity
AU751453B2 (en) Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
JP2019077728A (ja) ピリミジニルチロシンキナーゼ阻害剤
TWI745271B (zh) 全身紅斑性狼瘡之治療
CN1520290A (zh) 含铜胺氧化酶的碳环肼基抑制剂
CN1284077A (zh) 具有磷酸二酯酶iv抑制活性的嘌呤衍生物
JP2002517401A (ja) 環状ボロプロリン化合物
EP3122360B1 (en) Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
CN1353713A (zh) 依赖细胞周期蛋白的激酶2和IκB－α的嘌呤抑制剂
US20140294870A1 (en) Autoimmune and Inflammatory Disorder Therapy
KR20230019940A (ko) Irak 분해제의 결정성 형태
EP0623133B1 (en) Substituted amino alkyl compounds
JP2010248224A (ja) 治療又は予防薬
JP2024536863A (ja) イミダゾピリダジンｉｌ－１７阻害剤化合物
EP4257589A1 (en) Triazolo pyrazine compound and use thereof
Zhao et al. Novel phloroglucinol derivative Compound 21 protects experimental autoimmune encephalomyelitis rats via inhibiting Th1/Th17 cell infiltration
Ling et al. Shared Epitope–Antagonistic Ligands: A New Therapeutic Strategy in Mice With Erosive Arthritis
CA2699590A1 (fr) Utilisation de derives de purine pour la fabrication d'un medicament

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication